• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Liminal takes buyout from top shareholder at peach of a price

    FIERCE BIOTECH

    Annexon, Liminal shrink pipelines to focus on possible homeruns

    FIERCE BIOTECH

    Liminal Biosciences to Present at H.C. Wainwright 24th Annual Global Conference

    PRNEWSWIRE

    Liminal BioSciences Announces Termination of Legacy CDMO Contract

    BIOPHARMA APAC

    Liminal BioSciences Announces First Subject Dosed in Phase 1a Trial

    PRNEWSWIRE

    Ocugen Signs LOI to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada

    GLOBENEWSWIRE

    Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

    PRNEWSWIRE

    Liminal BioSciences Announces Signature of a Share Purchase Agreement

    BIOSPACE

    Liminal BioSciences Provides an Update on Currently Planned Clinical Fezagepras

    PRNEWSWIRE

    Liminal Announces Closing of Divestiture of Plasma Collection Centers

    PRNEWSWIRE

    Delic`s Acquisition Target, Complex Biotech Discovery Announces Closing

    BIOSPACE

    Liminal Enters into Agreement with Kedrion to Divest Its Plasma Collection

    PRNEWSWIRE

    Liminal Provides Update on Business Strategy and Focus on Small Molecule

    PRNEWSWIRE

    Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple

    PRNEWSWIRE

    Liminal BioSciences Presents Two Case Histories on Investigational

    PRESS RELEASE

    Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim

    BIOSPACE

    Liminal BioSciences Announces Upcoming Presentations for Ryplazim®

    PRNEWSWIRE

    Liminal BioSciences Provides Update on Progress on BLA for Ryplazim®

    PRNEWSWIRE

    Liminal BioSciences Announces Resubmission of Biologics License Application

    DRUG-DEV

    Liminal resubmits Biologics License Application to U.S. FDA for Ryplazim

    PRNEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.